Antiviral compounds

Abstract

The present invention discloses compounds of Formula (I): wherein the variables in Formula (I) are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula (I) in the prevention or treatment of HCV infection.

1 - 20 . (canceled) 
     
     
         21 . A compound of formula I: 
       
         
           
           
               
               
           
         
       
       wherein: 
       A is unsaturated or partially unsaturated monocyclic or bicyclic heteroaryl or monocyclic or spirocyclic heterocycloalkyl; 
       each R 1  is independently halo, halo lower alkyl, or lower alkyl sulfonyl; 
       m is 0, 1, or 2; 
       each R 2  is independently halo, lower alkoxy, oxo, amino, lower alkyl, C(═O)OR 2′ , S(═O)R 2′ , S(═O) 2 NHR 2′ , hydroxyl lower alkyl, C(═O)NHR 2′ , or C(═O)R 2′ ; 
       n is 0, 1, or 2; and 
       R 2′  is lower alkyl, halo lower alkyl, or adamantyl, 
       or a pharmaceutically acceptable salt thereof. 
     
     
         22 . The compound of  claim 21 , wherein m is 1. 
     
     
         23 . The compound of  claim 22 , wherein m is 2. 
     
     
         24 . The compound of  claim 23 , wherein one R 1  is halo and the other is halo lower alkyl. 
     
     
         25 . The compound of  claim 23 , wherein both R 1  are halo. 
     
     
         26 . The compound of  claim 21 , wherein n is 0. 
     
     
         27 . The compound of  claim 21 , wherein n is 1. 
     
     
         28 . The compound of  claim 21 , wherein n is 2. 
     
     
         29 . The compound of  claim 21 , wherein A is pyridinyl, pyrimidinyl, pyridazinyl, triazolyl, tetrazolyl, piperazinyl, 2,6-diaza-spiro[3.3]heptanyl, azetidinyl, thiophenyl, or pyrazolyl. 
     
     
         30 . The compound of  claim 29 , wherein R 2  is halo, lower alkoxy, oxo, amino, lower alkyl, C(═O)OR 2′ , S(═O) 2 R 2′ , S(═O) 2 NHR 2′ , hydroxyl lower alkyl, C(═O)NHR 2′ , or C(═O)R 2′ . 
     
     
         31 . The compound of  claim 30 , wherein R 2′  is lower alkyl or halo lower alkyl. 
     
     
         32 . A method for preventing a Hepatitis C Virus (HCV) infection, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of claim  1 . 
     
     
         33 . The method of  claim 33 , further comprising administering to a patient in need thereof a therapeutically effective amount of an immune system suppressant. 
     
     
         34 . A method for treating a Hepatitis C Virus (HCV) infection, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound of claim  1 . 
     
     
         35 . The method of  claim 32  or  34 , further comprising administering a combination of antiviral agents that inhibits replication of HCV. 
     
     
         36 . The method of  claim 32 , further comprising administering an immune system modulator or an antiviral agent that inhibits replication of HCV, or a combination thereof. 
     
     
         37 . The method of  claim 36 , wherein the immune system modulator is an interferon or a chemically derivatized interferon. 
     
     
         38 . The method of  claim 36 , wherein the antiviral agent is selected from the group consisting of a HCV protease inhibitor, a HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV NS5A inhibitor, or any combination thereof. 
     
     
         39 . A pharmaceutical composition, comprising a therapeutically effective amount of a compound of  claim 21  and a pharmaceutically acceptable excipient. 
     
     
         40 . The method of  claim 34 , further comprising administering an immune system modulator or an antiviral agent that inhibits replication of HCV, or a combination thereof. 
     
     
         41 . The method of  claim 40 , wherein the immune system modulator is an interferon or a chemically derivatized interferon. 
     
     
         42 . The method of  claim 40 , wherein the antiviral agent is selected from the group consisting of a HCV protease inhibitor, a HCV polymerase inhibitor, a HCV helicase inhibitor, a HCV NS5A inhibitor, or any combination thereof.